{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:40:08Z","timestamp":1793364008236,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We compared the outcomes of unrelated donor (URD, n = 358) with human leukocyte antigen (HLA)\u2013matched sibling donor (MSD, n = 226) transplantations in patients with acute myeloid leukemia (AML) in first complete remission (CR1) having unfavorable cytogenetics at diagnosis. Unfavorable cytogenetic abnormalities were: complex (\u2265 3 abnormalities), 32%; and noncomplex involving chromosome 7, 25%; chromosome 5, 9%; 11q or MLL rearrangements, 18%; t(6;9), 5%; and other noncomplex, 10%. URDs were HLA-well-matched (n = 254; 71%) or partially-matched (n = 104; 29%). Three-year leukemia-free survival (LFS) for MSD was 42% (95% confidence interval [CI], 35%-48%) compared with 34% (95% CI, 28%-41%) for HLA-well-matched URD and 29% (95% CI, 20%-39%) for partially-matched URD (P = .08). In multivariate analysis, HLA-well-matched URD and MSD yielded similar LFS (relative risk [RR] = 1.1, 95% CI, 0.86-1.40, P = .44) and overall survival (OS; RR = 1.06, 95% CI, 0.83-1.37, P = .63). LFS and OS were significantly inferior for HLA-partially-matched URD recipients, those with prior myelodysplastic syndrome, and those older than 50 years. All cytogenetic cohorts had similar outcomes. Patients with chronic graft-versus-host disease had a significantly lower risk of relapse (RR = 0.68, 95% CI, 0.47-0.99, P = .05). Hematopoietic cell transplantation (HCT) using HLA-well-matched URD and MSD resulted in similar LFS and OS in AML patients in CR1 with unfavorable cytogenetics. Outcomes of HCT from HLA-partially- matched URD were inferior.<\/jats:p>","DOI":"10.1182\/blood-2010-04-278317","type":"journal-article","created":{"date-parts":[[2010,6,11]],"date-time":"2010-06-11T01:55:13Z","timestamp":1276221313000},"page":"1839-1848","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":166,"title":["Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis"],"prefix":"10.1182","volume":"116","author":[{"given":"Vikas","family":"Gupta","sequence":"first","affiliation":[{"name":"Princess Margaret Hospital, University of Toronto, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"He","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent R.","family":"Logan","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Copelan","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"Celgene Corporation, Summit, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna J.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Emory University Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klumpp","sequence":"additional","affiliation":[{"name":"Fox Chase\u2013Temple BMT Program, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"University Hospitals Case Medical Center, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Marks","sequence":"additional","affiliation":[{"name":"Bristol Children's Hospital, Bristol, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Martino","sequence":"additional","affiliation":[{"name":"Hospital de la Santa Creu i Sant Pau, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Rizzieri","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Rambam Medical Center, Haifa, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Sabloff","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Blood and Marrow Transplant Program, Ottawa, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"Emory University Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Barnes Jewish Hospital, St Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Bunjes","sequence":"additional","affiliation":[{"name":"Universitatsklinikum Ulm, Ulm, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"University of Minnesota Medical Center, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111722505368800_B1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/cncr.20945","article-title":"Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.","volume":"103","author":"Yanada","year":"2005","journal-title":"Cancer"},{"issue":"22","key":"2019111722505368800_B2","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/jama.2009.813","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.","volume":"301","author":"Koreth","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"2019111722505368800_B3","article-title":"Treatment of patients up to 60 years with high risk AML: final results of the AML SHG-Hannover 01\/99 Trial [abstract].","volume":"108","author":"Krauter","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"2019111722505368800_B4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/leu.2008.352","article-title":"Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.","volume":"23","author":"Basara","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2019111722505368800_B5","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111722505368800_B6","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings.","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111722505368800_B7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bbmt.2007.01.073","article-title":"Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.","volume":"13","author":"Moore","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"32","key":"2019111722505368800_B8","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1200\/JCO.2007.15.5184","article-title":"Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group.","volume":"26","author":"Schetelig","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111722505368800_B9","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.2005.03.1765","article-title":"Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.","volume":"24","author":"Hegenbart","year":"2006","journal-title":"J Clin Oncol"},{"issue":"36","key":"2019111722505368800_B10","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","article-title":"Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10\/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.","volume":"24","author":"Yakoub-Agha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111722505368800_B11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bmt.2009.141","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.","volume":"45","author":"Ljungman","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"2019111722505368800_B12","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1419.1419","article-title":"Allogeneic stem cell transplantation in adult patients with acute myeloid leukemia: to transplant or not to transplant? A systematic review of international guidelines [abstract].","volume":"114","author":"Hubel","year":"2009","journal-title":"Blood"},{"issue":"2","key":"2019111722505368800_B13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbmt.2007.12.005","article-title":"The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in adults.","volume":"14","author":"ASBMT Position Statement","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2019111722505368800_B14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bmt.1705973","article-title":"Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.","volume":"41","author":"Sierra","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111722505368800_B15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2141.2006.06314.x","article-title":"Guidelines on the management of acute myeloid leukaemia in adults.","volume":"135","author":"Milligan","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111722505368800_B16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2019111722505368800_B17","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2004-03-0803","article-title":"Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.","volume":"104","author":"Flomenberg","year":"2004","journal-title":"Blood"},{"issue":"13","key":"2019111722505368800_B18","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2019111722505368800_B19","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515","article-title":"Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient.","volume":"92","author":"Petersdorf","year":"1998","journal-title":"Blood"},{"issue":"7","key":"2019111722505368800_B20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111722505368800_B21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2005.1.384","article-title":"Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?","author":"Giralt","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"13","key":"2019111722505368800_B22","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111722505368800_B23","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111722505368800_B24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease.","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111722505368800_B25","doi-asserted-by":"crossref","DOI":"10.1007\/b97377","volume-title":"Survival Analysis: Techniques of Censored and Truncated Data","author":"Klein","year":"2003","edition":"2nd ed"},{"key":"2019111722505368800_B26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"4","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"9","key":"2019111722505368800_B27","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2006-06-025627","article-title":"Results of a HOVON\/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?","volume":"109","author":"Cornelissen","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2019111722505368800_B28","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC\/GIMEMAAML-10 trial.","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"issue":"13","key":"2019111722505368800_B29","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2008-07-163212","article-title":"The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.","volume":"113","author":"Ringden","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111722505368800_B30","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"29","key":"2019111722505368800_B31","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111722505368800_B32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1200\/JCO.2004.06.102","article-title":"Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.","volume":"22","author":"Ringden","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111722505368800_B33","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2005-07-2661","article-title":"Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.","volume":"107","author":"Khoury","year":"2006","journal-title":"Blood"},{"issue":"33","key":"2019111722505368800_B34","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1200\/JCO.2006.06.1663","article-title":"Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation.","volume":"24","author":"Dekker","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/11\/1839\/1329137\/zh803710001839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/116\/11\/1839\/1329137\/zh803710001839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:20:20Z","timestamp":1740176420000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/116\/11\/1839\/27424\/Comparable-survival-after-HLAwellmatched-unrelated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,16]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,9,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2010-04-278317","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,16]]}}}